Evidence map›Paper›PMID 42098080›Full record

ReviewOncogenesis2026

Metabolic modulation of immune cell function: mechanisms and therapeutic implications in cancer immunotherapy.

Nina Fenouille, Camille Lobry, Lina Benajiba, Alexandre Puissant

Abstract readReview
In one paragraph

Review in Oncogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nina FenouilleINSERM UMR 1342, Institut de Recherche Saint Louis, Institut de la Leucémie Paris-Saint Louis, Université Paris Cité, Paris, France.
Camille Lobry *INSERM UMR 1342, Institut de Recherche Saint Louis, Institut de la Leucémie Paris-Saint Louis, Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0003-0550-4921
Lina Benajiba *INSERM UMR 1342, Institut de Recherche Saint Louis, Institut de la Leucémie Paris-Saint Louis, Université Paris Cité, Paris, France.
Alexandre Puissant *INSERM UMR 1342, Institut de Recherche Saint Louis, Institut de la Leucémie Paris-Saint Louis, Université Paris Cité, Paris, France. alexandre.puissant@inserm.fr.ORCID http://orcid.org/0000-0002-3997-9282

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-23-IAHU-0005EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101088563EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101117339Institut National Du Cancer (French National Cancer Institute) INCa-DGOS-INSERM-ITMO Cancer_18008Ligue Contre le Cancer ATIP-AVENIR
6 · The paper itself

Abstract

Immune cell function is remarkably plastic, allowing T cells, NK cells, and macrophages to transition from resting or quiescent states to proliferative, cytotoxic, or inflammatory programs. These functional shifts are tightly coupled to metabolic reprogramming, which not only fuels energy and biosynthesis but also shapes epigenetic and transcriptional landscapes that guide immune responses. In this review, we highlight how intrinsic metabolic pathways which include glycolysis, fatty acid oxidation, amino acid metabolism, and TCA cycle intermediates, regulate T and NK cell proliferation, cytotoxicity, memory formation, and epigenetic programs. We also examine macrophages, whose polarization into pro-inflammatory M1 or tissue-reparative M2 states is orchestrated by distinct metabolic programs such as arginine metabolism, oxidative phosphorylation, and fatty acid oxidation, with consequences for local immune regulation. We then explore how tumors exploit these metabolic dependencies to create hostile microenvironments that restrict nutrients, accumulate immunosuppressive metabolites, and dampen immune cell activity. Finally, we discuss emerging metabolic interventions designed to restore immune fitness, enhance the efficacy of immune checkpoint inhibitors, and improve the persistence and cytotoxicity of adoptive T cell therapies, including CAR-T cells, in nutrient-deprived and hypoxic tumor niches. By linking immune cell plasticity to metabolic control, this review provides a framework for understanding how metabolism shapes immunity and identifies strategies to harness these pathways for next-generation cancer immunotherapies.

Identifiers

PMID42098080
PMCPMC13315717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.